ClinicalTrials.gg
RecruitingNCT06653569INFLUENTUpdated May 1, 2026

Efficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment)

A Phase 3 interventional study of Baloxavir Marboxil and Placebo in Influenza Disease; Flu, sponsored by Dre Pauline Vetter. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Dre Pauline Vetter · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
484
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.

Planned enrollment
9th of 18
484 · median 483
Started
2024
with 1 other
Phase 3
12 of 18
5 open now
Registered
14th of 18
by date
Lead sponsor
1 of 18
Dre Pauline Vetter

Among the 18 studies testing baloxavir in Influenza, Human, this one is the 9th largest by planned enrollment, is one of 2 that started in 2024, is one of 12 in phase 3, and was the 14th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About baloxavir

baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baloxavir in Influenza, Human, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to find out if the medication called baloxavir marboxil (sold under the brand name Xofluza®) can help to reduce the time needed to recover from flu when patients need an hospitalization. Patients infected by influenza and requiring a hospitalization will be approched to be included in the study.

The main questions are:

  1. When someone is hospitalized with a severe influenza infection, does baloxavir help to reduce the time needed to recover?
  2. Can baloxavir marboxil help to shorten the amount of time people need to stay in the hospital with severe flu?
  3. Can baloxavir marboxil help to reduce the risk of life-threatening complications as well as of death due to severe flu?
  4. Can baloxavir reduce duration of contagiousness?

To be able to measure the above, the investigators will compare two groups of patients: One group receiving baloxavir marboxil, the other group receiving a mock treatment called placebo.

Participants will:

  • Take one single dose of baloxavir marboxil or placebo soon after hospitalization.
  • Vital signs will be followed three times per day during hospital stay.
  • Have a nose swab to detect the presence of influenza virus on the first and third day of trial participation.
  • Answer to a short quality of life questionnaire on the phone 3 months after receiving the study treatment.
Read the detailed description

Background: Influenza virus is a major source of seasonal outbreaks and is the leading candidate for a future pandemic. Each winter thousands of people are hospitalized with infection complications. The most at risk are the very young (\< 5 years), the elderly (>65 years old) and those with a weak immune system. When a person is hospitalized because of the flu, it is not always clear if the administration of a specific medicine that fights the virus (called an antiviral) will help.

Most studies looked at antivral drug benefits among people with mild flu, who didn't need to be hospitalized. They found that if the antiviral is started early (up to two days after the symptoms started), it can make the symptoms go away a little faster. But for people in the hospital, especially if it's been more than two days since their symptoms started, it is not so sure if antiviral drugs still help. Clinical research involving patients hospitalized for disease complications is few and of lesser quality. While some indicate that early treatment might be beneficial, there is no scientific agreement about treatment benefits. Therefore, recommendations and antiviral prescription varies between hospitals and physicians.

In Switzerland two antiviral drugs are authorized to treat the flu: Tamiflu® and Xofluza®.

Study aims and methods: The goal of this industry-independent trial is to measure the benefits of Xofluza® compared to placebo (mock medication) in adult patients hospitalized for the flu.

Choice of the medication: The investigators chose Xofluza® instead of Tamiflu® because it is very simple to use (only a single pill instead of twice a day Tamiflu® for 5 days), it has fewer side effects and can be safely given to patients with a wide range of chronic diseases.

Importance: This study is very important because it could lead to a Swiss and international consensus about the utility of antiviral treatment in hospitalized patients.

If beneficial, Xofluza® might be the drug of choice in a future pandemic, when access to a simple to administer and easily stored drug effective at all stages of the illness with few side effects would be of utmost importance.

However, if the trial doesn't show any benefit of Xofluza® administration, antiviral treatment prescription won't be recommended, preserving patients from unneeded medication and from its potential side effects and saving ressources.

Tailoring antiviral use will also help prevent the risk of the virus becoming resistant which might happen in case of overuse.

Patient and public involvement: During the preparation of the study, patient representatives were involved in the development of the research idea, in the discussion concerning its ethical aspects, the feasibility of recruitment, and the selection of questionnaires to measure treatment benefits. They participated in the revision of the lay summary as well. The informed consent form has been developped together with them, in our communication efforts targeting potential participants at the start as well as in the dissemination of the results at the end of the study. Patients representatives also developped together with the investigators the strategy of participants recruitment.

03

Conditions studied

  • Influenza Disease; Flu

Browse trials for

Keywords

  • antiviral treatment
  • baloxavir marboxil
  • influenza complications
  • hospitalization
  • severe influenza
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Participant or participant representative capable of giving signed .
  • Positive reverse transcriptase-polymerase chain reaction (RT-PCR) for influenza A and/or B confirmed on arespiratory tract sample.
  • Patient requiring hospitalization.
  • National Early Warning Score 2 (NEWS2) of ≥4 at planned randomization

Exclusion criteria

Exclusion Criteria:

  • Ongoing pregnancy or breastfeeding (self-reported by the participant or diagnosed by the treating phyisician)
  • Known to baloxavir or to the placebo
  • Participant weighing \< 40 kg
  • Patients already on NAI therapy for the current influenza episode for > 24 hours at the time of randomization.
  • Prior treatment with baloxavir for the current influenza epidose
  • defined as 1) cancer treatment with significant negative effect on the immune system; 2) immunosuppressive therapy (treatments comprising a dose of ≥20 mg/day prednisone or equivalent when administered for ≥ 2 weeks, biological therapies, sparing drugs); 3) infection if \< 500/µL; 4) organ or stem cell transplantation; 5) patients on the waiting list for a transplant
  • Severe underlying respiratory comorbidity requiring long-term oxygenotherapy at home.
  • Severe disease requiring ICU care directly at hospitalization.
  • Severe hepatic insufficiency or any other severe medical condition when participation in the study puts the patient at risk according to the investigator's judgment.
  • History of inclusion in this study during a previous influenza season
  • Inclusion in another interventional study with an drug 30 days before inclusion in the study.
  • Unability to consent or patient representative unable to consent.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
484 participants (estimated)

Study arms

  • Experimental
    antiviral treatment

    baloxavir marboxil

    Drug: Baloxavir Marboxil

  • Placebo comparator
    placebo

    Pacebo

    Drug: Placebo

Interventions

  • DrugBaloxavirStudies of BaloxavirBaloxavir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The antiviral baloxavir marboxil administered in one unique dose. 1 capsule (40 mg) if participant weighs \< 80 kg; 2 capsules (80 mg) if participant weighs ≥ 80 kg

  • DrugPlacebo

    Patients in the placebo group will receive one unique dose of placebo. 1 capsule if participant weighs \< 80 kg; 2 capsules (80 mg) if participant weighs ≥ 80 kg.

06

What researchers measure

Primary outcomes

  1. Time to clinical improvement

    The primary outcome is the time to clinical improvement, calculated from treatment administration, assessed by time to hospital discharge alive or time to a NEWS2 score of 2 or lower maintained for 24 h, whichever comes first.

    Time frame: From treatment administration to hospital discharge or NEWS2 score of 2 or lower maintained for 24 h, whichever comes first, assessed up to day 90

Secondary outcomes

  1. Clinical status severity score

    A patient's clinical improvement can be assessed by an additional scoring system. Here, a 6-point ordinal scale will be used to capture the different clinical trajectories of the patients (1: discharged; 2: subacute care; 3: acute care without respiratory failure; 4: acute care with respiratory failure; 5: intensive care unit; 6: death) and to measure antiviral treatment's potential benefits with a different tool.

    Time frame: At 7 days post treatment administration

  2. Duration of hospitalization

    Duration of hospitalization post-treatment administration, measured in hours

    Time frame: From treatment administration to hospital discharge, assessed up to day 90

  3. Duration of Oxigen supplementation

    Duration of O2 supplementation post-treatment administration (in hours).

    Time frame: From treatment administration to waining of oxygen therapy, assessed up to day 90 (in patients requiring oxygen).

  4. In-hospital clinical failure

    In-hospital clinical failure, defined as death or ICU or ICMU admission during hospitalization or up to 30 days post treatment administration in case of prolonged hospital stay.

    Time frame: From treatment administration to the end of hospital stay, maximum 30 days after treatment administration

  5. Mortality

    Mortality due to any cause.

    Time frame: From treatment administration during 90 days

  6. Influenza-related complications

    Influenza-related complications, diagnosed by the treating physician (composite outcome defined as pneumonia, sepsis, acute lung injury or ARDS, encephalitis/encephalopathy, myo or -pericarditis, otitis, sinusitis as well as any cardiovascular event (cardiac decompensation, myocardial infarction or stroke))

    Time frame: From treatment administration during 90 days

  7. Antibiotic consumption

    Number of antibiotic days (AD).

    Time frame: From treatment administration to the end of hospital stay, maximum 30 days after treatment administration

  8. Change in quality of life at D90

    Impact of antiviral treatment on patient quality of life after discharge using the EQ-5D-5L scale (5-level EQ-5D version). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Time frame: At day 90-days post treatment administration

  9. Viral shedding

    Number of participants with detectable RNA in respiratory sample on day 3 after treatment administration.

    Time frame: On day 3 after treatment administration.

  10. Duration of infectious viral shedding

    Infectious viral load in respiratory sample at day 3 post-treatment administration.

    Time frame: On day 3 post-treatment administration

Other outcomes

  1. Serious adverse events, SAR and SUSAR

    Safety outcomes will be SAE unrelated to the natural history of influenza, SAR and SUSAR.

    Time frame: From treatment administration to the end of hospital stay, maximum 30 days after treatment administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hosszu-Fellous K, Vetter P, Agoritsas T, Kaiser L. Which trial do we need? Randomized, placebo-controlled trial of antiviral treatment in patients hospitalized for influenza. Clin Microbiol Infect. 2024 May;30(5):567-569. doi: 10.1016/j.cmi.2024.01.025. Epub 2024 Feb 3. No abstract available. PubMed 38316358 ↗
  • Hosszu-Fellous K, Poncet A, Cabecinhas ARG, Schibler M, Meyer B, Prendki V, Huttner A, Carballo S, Pouillon M, Slankamenac K, Bart PA, Bernasconi E, Manuel O, Mombelli M, Mueller NJ, Kaiser L, Vetter P. Antiviral treatment in adult patients hospitalized for influenza: study protocol for a multi-center, randomized, placebo-controlled trial on the efficacy of baloxavir marboxil to reduce time to clinical improvement and the risk for severe complications (the INFLUENT trial). Trials. 2025 Nov 24;26(1):538. doi: 10.1186/s13063-025-09248-0. PubMed 41286959 ↗

Individual participant data

Plan to share: Yes — The investigators plan to share individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). IPD can be shared with investigators whose proposed use of the data has been approved by an independent review committee, for, as an example, individual participant data meta-analysis. The approval of the biobank regulation committee, which includes the coordinating PI, the sites PI and the responsibles of the biobank is also required on a case by case basis.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 3 months and up to 10 years after publication.

Access criteria: IPD can be shared with investigators whose proposed use of the data has been approved by an independent review committee. The approval of the biobank regulation committee, which includes the coordinating PI, the sites PI and the responsibles of the biobank is also required on a case by case basis.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Apr 2027, 28 months after the start.

Of 35 non-industry phase 3 interventional studies under Influenza, Human, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 41. This study's planned 28 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2024
First posted
Oct 22, 2024
StartActual
Dec 13, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Sep 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06653569
Lead sponsor
Dre Pauline Vetter
Collaborators
Swiss National Science Foundation, University Hospital, Geneva, University of Geneva, Switzerland, Ente Ospedaliero Cantonale, Ticino, Switzerland, Centre Hospitalier Universitaire Vaudois (Switzerland), University of Zurich, University Hospital, Zürich
Responsible party
Dre Pauline Vetter (Senior staff physician, University Hospital, Geneva) — Sponsor-investigator
First posted
Oct 22, 2024
Start date
Dec 13, 2024
Primary completion
Apr 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
May 1, 2026

Study contacts

Pauline Vetter, MD
Contact
Pauline.Vetter@hug.ch
+41 79 55 39 761
Krisztina Hosszu-Fellous, MD
Contact
krisztina.hosszu-fellous@hug.ch
+41795522953
Pauline Vetter, MD
principal investigator · University Hospital, Geneva
Nicolas Muller, Professor
principal investigator · Department of Infectious Diseases and Hospital epidemiology, University Hospital Zürich
Matteo Mombelli, MD
principal investigator · Department of internal medicine, Locarno Regional Hospital EOC
Oriol Manuel, Pr
principal investigator · Center for organ transplantation, Lausanne University Hospitals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baloxavir

Start the discussion